Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

6.89
+0.09501.40%
Volume:26.48K
Turnover:184.48K
Market Cap:42.60M
PE:-2.81
High:7.38
Open:7.03
Low:6.78
Close:6.79
52wk High:13.69
52wk Low:3.76
Shares:6.19M
Float Shares:3.00M
Volume Ratio:0.66
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4500
EPS(LYR):-2.4500
ROE:-196.92%
ROA:-69.33%
PB:0.80
PE(LYR):-2.81

Loading ...

Aligos Therapeutics files initial beneficial ownership statement for Nikhil Aneja, Principal Accounting Officer

Reuters
·
Feb 20

Aligos Therapeutics Appoints New Principal Accounting Officer

TIPRANKS
·
Feb 05

Aligos Therapeutics ernennt Nikhil Aneja zum Principal Accounting Officer

Reuters
·
Feb 05

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

TIPRANKS
·
Jan 30

Aligos Therapeutics Grants Stock Options to New Employees Under 2024 Inducement Plan

Reuters
·
Jan 30

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 30

BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies

Reuters
·
Jan 21

BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances

Reuters
·
Jan 21

Aligos Therapeutics provides update for Phase 2 study of pevifoscorvir sodium

TIPRANKS
·
Jan 21

Aligos Therapeutics Chief Medical Officer Hardean Achneck Resigns

Reuters
·
Jan 21

Aligos Therapeutics Inc: Study Remains on Track to Complete Enrollment, With Topline Data Expected in 2027

THOMSON REUTERS
·
Jan 21

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

GlobeNewswire
·
Jan 21

Aligos Therapeutics management to meet virtually with Piper Sandler

TIPRANKS
·
Jan 21

Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market

TIPRANKS
·
Jan 16

Aligos Therapeutics appoints James Hassard as EVP, CCO

TIPRANKS
·
Jan 13

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

GlobeNewswire
·
Jan 13

Aligos Therapeutics Initiated at Buy by UBS

Dow Jones
·
Jan 08

UBS Initiates Aligos Therapeutics at Buy With $20 Price Target

MT Newswires Live
·
Jan 07

Aligos Therapeutics Grants Stock Options to New Hires Under 2024 Inducement Plan

Reuters
·
Dec 12, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 12, 2025